Effects Of Korea's New Drug-Pricing System Still Murky
This article was originally published in PharmAsia News
Executive Summary
SEOUL - Nearly a year after the South Korean Health Ministry announced new policies aimed at eradicating bribery and promoting more transparent drug pricing, effects of a new drug-pricing system remain unclear, industry watchers say
You may also be interested in...
Pricing And Commercial Strategies For Emerging Markets Need To Be Built Into Drug Development Programs Early - DIA Conference
CHICAGO - Emerging markets represent a plethora of opportunity for multinational pharma companies, but they also represent a confusing mix of pricing and reimbursement policies that change rapidly and are not always clear
Pricing And Commercial Strategies For Emerging Markets Need To Be Built Into Drug Development Programs Early - DIA Conference
CHICAGO - Emerging markets represent a plethora of opportunity for multinational pharma companies, but they also represent a confusing mix of pricing and reimbursement policies that change rapidly and are not always clear
Korea Moves To Cut Drug Prices Of Seven Pharma Companies Over Rebates
SEOUL - In its first action following a warning in 2009 about drug rebates, the Korea Ministry of Health and Welfare is moving to cut market prices for 131 products manufactured by seven local Korean pharma companies by as high as 20%